bluebird gets accelerated assessment ahead of MAA for β-thalassemia gene therapy

bluebird bio Inc. (NASDAQ:BLUE) said EMA’s CHMP granted LentiGlobin BB305 accelerated assessment to treat patients with transfusion-dependent β-thalassemia. The company plans to submit an MAA for LentiGlobin BB305 this half...